Prognostic Impact and Immunotherapeutic Implications of NETosis-related Prognostic Model in Clear Cell Renal Cell Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 May 27

PMID 38801430

Authors

Xingjun Mao

Wen Huang

Qing Xue

Xiaolei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded.

Methods: A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays.

Results: The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients' immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays.

Conclusion: The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.

References

De Marco S, Torsello B, Minutiello E, Morabito I, Grasselli C, Bombelli S . The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells. FEBS Lett. 2022; 597(8):1098-1113. DOI: 10.1002/1873-3468.14531. View

Yin Y, Dai H, Sun X, Xi Z, Zhang J, Pan Y . HRG inhibits liver cancer lung metastasis by suppressing neutrophil extracellular trap formation. Clin Transl Med. 2023; 13(6):e1283. PMC: 10230156. DOI: 10.1002/ctm2.1283. View

Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J . TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2022; 51(D1):D1425-D1431. PMC: 9825603. DOI: 10.1093/nar/gkac959. View

Weide L, Schedel F, Weishaupt C . Neutrophil Extracellular Traps Correlate with Tumor Necrosis and Size in Human Malignant Melanoma Metastases. Biology (Basel). 2023; 12(6). PMC: 10295294. DOI: 10.3390/biology12060822. View

Guillotin F, Fortier M, Portes M, Demattei C, Mousty E, Nouvellon E . Vital NETosis vs. suicidal NETosis during normal pregnancy and preeclampsia. Front Cell Dev Biol. 2023; 10:1099038. PMC: 9849884. DOI: 10.3389/fcell.2022.1099038. View

Vuong L, Kotecha R, Voss M, Hakimi A . Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2019; 9(10):1349-1357. PMC: 6774890. DOI: 10.1158/2159-8290.CD-19-0499. View

Papayannopoulos V . Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2017; 18(2):134-147. DOI: 10.1038/nri.2017.105. View

Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F . Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol Oncol. 2017; 35(7):461.e15-461.e27. DOI: 10.1016/j.urolonc.2017.02.011. View

Vorobjeva N, Chernyak B . NETosis: Molecular Mechanisms, Role in Physiology and Pathology. Biochemistry (Mosc). 2020; 85(10):1178-1190. PMC: 7590568. DOI: 10.1134/S0006297920100065. View

10.

Ghini V, Laera L, Fantechi B, Monte F, Benelli M, McCartney A . Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers (Basel). 2020; 12(12). PMC: 7760033. DOI: 10.3390/cancers12123574. View

11.

Li Q, Wei K, Zhang X, Lv Y, Li M, Zhou C . TIMP1 shapes an immunosuppressive microenvironment by regulating anoikis to promote the progression of clear cell renal cell carcinoma. Aging (Albany NY). 2023; 15(17):8908-8929. PMC: 10522382. DOI: 10.18632/aging.205005. View

12.

Adrover J, McDowell S, He X, Quail D, Egeblad M . NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell. 2023; 41(3):505-526. PMC: 10280682. DOI: 10.1016/j.ccell.2023.02.001. View

13.

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F . Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019; 19(5):397-407. DOI: 10.1080/14737159.2019.1607729. View

14.

Tamma R, Rutigliano M, Lucarelli G, Annese T, Ruggieri S, Cascardi E . Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019; 37(6):355.e11-355.e19. DOI: 10.1016/j.urolonc.2019.01.025. View

15.

Yu Z, Lu W, Su C, Lv Y, Ye Y, Guo B . Single-Cell RNA-seq Identification of the Cellular Molecular Characteristics of Sporadic Bilateral Clear Cell Renal Cell Carcinoma. Front Oncol. 2021; 11:659251. PMC: 8217644. DOI: 10.3389/fonc.2021.659251. View

16.

Kuai X, Ji Z, Zhang H . Mitochondrial uncoupling protein 2 expression in colon cancer and its clinical significance. World J Gastroenterol. 2010; 16(45):5773-8. PMC: 2997996. DOI: 10.3748/wjg.v16.i45.5773. View

17.

Lucarelli G, Rutigliano M, Loizzo D, di Meo N, Lasorsa F, Mastropasqua M . MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome. Int J Mol Sci. 2022; 23(22). PMC: 9696833. DOI: 10.3390/ijms232213968. View

18.

Zhang X, Wei X, Wang Y, Wang S, Ji C, Yao L . Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma. Front Oncol. 2022; 11:774279. PMC: 8766752. DOI: 10.3389/fonc.2021.774279. View

19.

Tang D, Kang R, Vanden Berghe T, Vandenabeele P, Kroemer G . The molecular machinery of regulated cell death. Cell Res. 2019; 29(5):347-364. PMC: 6796845. DOI: 10.1038/s41422-019-0164-5. View

20.

Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L . Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022; 7(1):286. PMC: 9376115. DOI: 10.1038/s41392-022-01110-y. View